The Swedish market for hormones in dosage excluding contraceptives and antibiotics has experienced considerable fluctuations over the last decade. The peak was in 2014, followed by a steep decline in 2015 and a gradual decrease thereafter, stabilizing slightly in the years following up to 2020. Notably, the market value in 2023 stood at 377.71 million USD. Recent assessments indicate a decline in market size by 11.67% in 2022 and a further reduction by 2.86% in 2023. The average annual compound growth rate over the past five years was negative, at -3.17%, highlighting a shrinking market.
Future trends to watch for include:
- Potential innovations in hormone application methods or therapeutic areas, which could rejuvenate the market.
- The impact of demographic changes, such as an aging population, potentially influencing hormone therapy demand.
- Increasing emphasis on biologic products and precise gene therapies may alter the traditional hormone therapy landscape.
- Regulatory changes and healthcare policy shifts that could affect market access and pricing.
